"She was able to answer some questions and referred them to appropriate company and embassy contacts to pursue their interest in obtaining experimental product," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
He added that the NIH employee was not working in any official capacity for the NIH at the time. She was working for a team led by CDC and the Defense Threat Reduction Agency.
The experimental drug was manufactured by San Diego-based Mapp Biopharmaceuticals, according to the National Institute of Allergy and Infectious Diseases.
According to Mapp’s website, its Ebola drug is a “cocktail” of monoclonal antibodies, which had been proven to work in monkey studies.
“When administered one hour after infection, all animals survived,” a 2012 company statement reads. “Two-thirds of the animals were protected even when the treatment, known as MB-003, was administered 48 hours after infection.”
When the vials arrived, those caring for Dr. Kent Brantly and missionary Nancy Writebol could not tell if there would be enough of the serum for both of them. Brantly said Writebol should get the dose first, but soon his condition worsened and doctors gave him the first dose. Doctors realized there was enough for both of them and gave Writebol the second dose shortly thereafter.
Within 20 minutes to an hour after getting the serum, Brantly "improved dramatically."
Brantly was flown from Liberia to Emory University Medical Center over the weekend for supportive care, where he shocked doctors by walking into the hospital.
Writebol is expected to fly out on Tuesday, and her appetite has reportedly improved.